Last reviewed · How we verify
EmSam
EmSam, marketed by the New York State Psychiatric Institute, holds a niche position in the psychiatric treatment landscape. The drug's key composition patent is set to expire in 2028, providing a period of market exclusivity. However, the lack of detailed revenue data and primary trial results poses a significant risk in assessing its commercial viability and therapeutic efficacy.
At a glance
| Generic name | EmSam |
|---|---|
| Also known as | Selegiline Transdermal |
| Sponsor | New York State Psychiatric Institute |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study to Assess the Skin Irritation and Sensitization of Selegiline TDS in Healthy Subjects (PHASE1)
- Determine the Bioavailability of Selegiline TDS 6mg/24 Hours vs EMSAM in Healthy Subjects
- Selegiline to Zelapar Switch Study in Parkinson Disease Patients (PHASE4)
- Pharmacokinetic Profile of Betahistine With and Without Selegiline in Healthy Volunteers (PHASE1)
- Safety and Effectiveness of the Selegiline "Patch" for Decreased Mental Function in HIV Patients (PHASE2)
- Dopaminergic Mechanism of Memory Impairment in Parkinson's Disease (PHASE4)
- Selegiline for the Treatment of Excessive Daytime Sleepiness in Parkinson's Disease (PHASE4)
- Clinical Trial of Selegiline Plus Docetaxel for the Treatment of Metastatic, Castrate-resistant Prostate Adenocarcinoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |